novel therapeutics for metabolic and endocrine disorders.
Company profile
Ticker
VKTX
Exchange
Website
CEO
Brian Lian
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Viking Therapeutics, PTY LTD ...
VKTX stock data
Latest filings (excl ownership)
8-K
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
26 Mar 24
8-K
Other Events
4 Mar 24
424B5
Prospectus supplement for primary offering
1 Mar 24
8-K
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
1 Mar 24
424B5
Prospectus supplement for primary offering
27 Feb 24
8-K
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
27 Feb 24
S-8
Registration of securities for employees
7 Feb 24
10-K
2023 FY
Annual report
7 Feb 24
8-K
Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
7 Feb 24
10-Q
2023 Q3
Quarterly report
25 Oct 23
Transcripts
VKTX
Earnings call transcript
2023 Q4
7 Feb 24
VKTX
Earnings call transcript
2023 Q3
25 Oct 23
VKTX
Earnings call transcript
2023 Q2
26 Jul 23
VKTX
Earnings call transcript
2023 Q1
26 Apr 23
VKTX
Earnings call transcript
2022 Q4
8 Feb 23
VKTX
Earnings call transcript
2022 Q3
27 Oct 22
VKTX
Earnings call transcript
2022 Q2
27 Jul 22
VKTX
Earnings call transcript
2022 Q1
28 Apr 22
VKTX
Earnings call transcript
2021 Q4
10 Feb 22
VKTX
Earnings call transcript
2021 Q3
4 Nov 21
Latest ownership filings
4
Marianna Mancini
27 Mar 24
4
Brian Lian
27 Mar 24
4
GREG ZANTE
27 Mar 24
4
Brian Lian
4 Mar 24
4
Marianna Mancini
4 Mar 24
4
GREG ZANTE
4 Mar 24
SC 13G/A
VIKING GLOBAL INVESTORS LP
14 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
4
Brian Lian
9 Feb 24
144
Notice of proposed sale of securities
9 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 37.19 mm | 37.19 mm | 37.19 mm | 37.19 mm | 37.19 mm | 37.19 mm |
Cash burn (monthly) | 10.78 mm | (no burn) | 9.09 mm | 7.65 mm | 6.55 mm | 5.56 mm |
Cash used (since last report) | 64.08 mm | n/a | 54.03 mm | 45.49 mm | 38.96 mm | 33.03 mm |
Cash remaining | -26.89 mm | n/a | -16.85 mm | -8.31 mm | -1.77 mm | 4.16 mm |
Runway (months of cash) | -2.5 | n/a | -1.9 | -1.1 | -0.3 | 0.7 |
Institutional ownership, Q3 2023
80.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 186 |
Opened positions | 31 |
Closed positions | 42 |
Increased positions | 63 |
Reduced positions | 49 |
13F shares | Current |
---|---|
Total value | 845.66 bn |
Total shares | 80.80 mm |
Total puts | 1.25 mm |
Total calls | 2.95 mm |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
FMR | 15.00 mm | $166.10 bn |
BLK Blackrock | 7.13 mm | $78.94 bn |
STT State Street | 6.41 mm | $70.97 bn |
Vanguard | 5.28 mm | $58.50 bn |
Viking Global Investors | 4.57 mm | $50.63 bn |
LGND Ligand Pharmaceuticals, Inc. - Ordinary Shares | 3.62 mm | $55.83 mm |
Alliancebernstein | 3.55 mm | $39.30 bn |
American Century Companies | 2.20 mm | $24.38 bn |
Balyasny Asset Management | 2.12 mm | $23.49 bn |
Geode Capital Management | 2.03 mm | $22.44 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Mar 24 | Greg Zante | Common Stock, par value $0.00001 per share | Payment of exercise | Dispose F | No | No | 83.34 | 16,610 | 1.38 mm | 207,361 |
27 Mar 24 | Greg Zante | Common Stock, par value $0.00001 per share | Grant | Acquire A | No | No | 0 | 31,667 | 0.00 | 223,971 |
27 Mar 24 | Marianna Mancini | Common Stock, par value $0.00001 per share | Payment of exercise | Dispose F | No | No | 83.34 | 16,610 | 1.38 mm | 363,565 |
27 Mar 24 | Marianna Mancini | Common Stock, par value $0.00001 per share | Grant | Acquire A | No | No | 0 | 31,667 | 0.00 | 380,175 |
27 Mar 24 | Lian Brian | Common Stock, par value $0.00001 per share | Payment of exercise | Dispose F | No | No | 83.34 | 153,948 | 12.83 mm | 2,266,453 |
27 Mar 24 | Lian Brian | Common Stock, par value $0.00001 per share | Grant | Acquire A | No | No | 0 | 221,667 | 0.00 | 2,420,401 |
1 Mar 24 | Greg Zante | Common Stock, par value $0.00001 per share | Payment of exercise | Dispose F | No | No | 85.22 | 20,093 | 1.71 mm | 192,304 |
1 Mar 24 | Greg Zante | Common Stock, par value $0.00001 per share | Grant | Acquire A | No | No | 0 | 31,667 | 0.00 | 212,397 |
1 Mar 24 | Marianna Mancini | Common Stock, par value $0.00001 per share | Payment of exercise | Dispose F | No | No | 85.22 | 16,958 | 1.45 mm | 348,508 |
1 Mar 24 | Marianna Mancini | Common Stock, par value $0.00001 per share | Grant | Acquire A | No | No | 0 | 31,667 | 0.00 | 365,466 |
News
Oppenheimer Maintains Outperform on Viking Therapeutics, Raises Price Target to $138
27 Mar 24
Oppenheimer Maintains Outperform on Viking Therapeutics, Raises Price Target to $138
26 Mar 24
Stocks Inch Higher, Tesla Rebounds, Bitcoin Holds Below $70,000: What's Driving Markets Tuesday?
26 Mar 24
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
26 Mar 24
BTIG Maintains Buy on Viking Therapeutics, Raises Price Target to $125
26 Mar 24
Press releases
Thinking about trading options or stock in NVIDIA, Vale, Viking Therapeutics, GigaCloud Technology, or Crowdstrike Holdings?
27 Mar 24
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
26 Mar 24
Thinking about trading options or stock in Advanced Micro Devices, Amazon.com, Intel, GSK, or Viking Therapeutics?
21 Mar 24
Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares
4 Mar 24
Thinking about buying stock in Volcon, Abeona Therapeutics, Agenus, Viking Therapeutics, or Compugen?
29 Feb 24